ELI LILLY AND COMPANY Share-based Payment Arrangement, Expense
ELI LILLY AND COMPANY (LLY) reported Share-based Payment Arrangement, Expense of $626.00 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AllocatedShareBasedCompensationExpense · last filed 2026-02-12
- ELI LILLY AND COMPANY share-based payment arrangement, expense for the quarter ending 2015-03-31 was $48.90M, a 27.68% increase year-over-year.
- ELI LILLY AND COMPANY share-based payment arrangement, expense for the quarter ending 2014-12-31 was $40.60M, a 2.01% increase year-over-year.
- ELI LILLY AND COMPANY share-based payment arrangement, expense for the quarter ending 2014-09-30 was $38.50M, a 6.35% increase year-over-year.
- ELI LILLY AND COMPANY share-based payment arrangement, expense for the quarter ending 2014-06-30 was $38.60M, a 14.54% increase year-over-year.
- ELI LILLY AND COMPANY share-based payment arrangement, expense for fiscal 2025 was $626.00M, a 3.10% decline from fiscal 2024.
- ELI LILLY AND COMPANY share-based payment arrangement, expense for fiscal 2024 was $646.00M, a 2.70% increase from fiscal 2023.
- ELI LILLY AND COMPANY share-based payment arrangement, expense for fiscal 2023 was $629.00M, a 69.50% increase from fiscal 2022.
- ELI LILLY AND COMPANY share-based payment arrangement, expense for fiscal 2022 was $371.10M, a 8.26% increase from fiscal 2021.
| Period end | Share-based Payment Arrangement, Expense 3 month | Share-based Payment Arrangement, Expense 6 month | Share-based Payment Arrangement, Expense 9 month | Share-based Payment Arrangement, Expense 12 month | Share-based Payment Arrangement, Expense 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | $626.00M 10-K · filed 2026-02-12 | ||||
| 2024-12-31 | $646.00M 10-K · filed 2026-02-12 | $645.60M 10-K · filed 2025-02-19 | |||
| 2023-12-31 | $629.00M 10-K · filed 2026-02-12 | $628.50M 10-K · filed 2024-02-21 | |||
| 2022-12-31 | $371.10M 10-K · filed 2025-02-19 | ||||
| 2021-12-31 | $342.80M 10-K · filed 2024-02-21 | ||||
| 2020-12-31 | $308.10M 10-K · filed 2023-02-22 | ||||
| 2019-12-31 | $306.80M 10-K · filed 2022-02-23 | ||||
| 2018-12-31 | $253.50M 10-K · filed 2021-02-17 | $279.50M 10-K · filed 2019-02-19 | |||
| 2017-12-31 | $256.30M 10-K · filed 2020-02-19 | $281.30M 10-K · filed 2018-02-20 | |||
| 2016-12-31 | $234.90M 8-K · filed 2019-10-24 | $255.30M 10-K · filed 2017-02-21 | |||
| 2015-12-31 | $217.80M 10-K · filed 2018-02-20 | ||||
| 2015-03-31 | $48.90M 10-Q · filed 2015-04-30 | $89.50M derived: sum of 2 quarters · filed 2017-02-21 | $128.00M derived: sum of 3 quarters · filed 2017-02-21 | $166.60M derived: sum of 4 quarters · filed 2017-02-21 | |
| 2014-12-31 | $40.60M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-21 | $79.10M derived: sum of 2 quarters · filed 2017-02-21 | $117.70M derived: sum of 3 quarters · filed 2017-02-21 | $156.00M 10-K · filed 2017-02-21 | |
| 2014-09-30 | $38.50M 10-Q · filed 2014-10-29 | $77.10M derived: sum of 2 quarters · filed 2014-10-29 | $115.40M 10-Q · filed 2014-10-29 | $155.20M derived: sum of 4 quarters · filed 2016-02-19 | |
| 2014-06-30 | $38.60M 10-Q · filed 2014-07-28 | $76.90M 10-Q · filed 2014-07-28 | $116.70M derived: sum of 3 quarters · filed 2016-02-19 | $152.90M derived: sum of 4 quarters · filed 2016-02-19 | |
| 2014-03-31 | $38.30M 10-Q · filed 2015-04-30 | $78.10M derived: sum of 2 quarters · filed 2016-02-19 | $114.30M derived: sum of 3 quarters · filed 2016-02-19 | $148.00M derived: sum of 4 quarters · filed 2016-02-19 | |
| 2013-12-31 | $39.80M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-19 | $76.00M derived: sum of 2 quarters · filed 2016-02-19 | $109.70M derived: sum of 3 quarters · filed 2016-02-19 | $144.90M 10-K · filed 2016-02-19 | |
| 2013-09-30 | $36.20M 10-Q · filed 2014-10-29 | $69.90M derived: sum of 2 quarters · filed 2014-10-29 | $105.10M 10-Q · filed 2014-10-29 | $146.30M derived: sum of 4 quarters · filed 2015-02-19 | |
| 2013-06-30 | $33.70M 10-Q · filed 2014-07-28 | $68.80M 10-Q · filed 2014-07-28 | $110.10M derived: sum of 3 quarters · filed 2015-02-19 | $144.50M derived: sum of 4 quarters · filed 2015-02-19 | |
| 2013-03-31 | $35.20M 10-Q · filed 2014-04-28 | $76.40M derived: sum of 2 quarters · filed 2015-02-19 | $110.80M derived: sum of 3 quarters · filed 2015-02-19 | $145.60M derived: sum of 4 quarters · filed 2015-02-19 | |
| 2012-12-31 | $41.20M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-19 | $75.60M derived: sum of 2 quarters · filed 2015-02-19 | $110.40M derived: sum of 3 quarters · filed 2015-02-19 | $141.50M 10-K · filed 2015-02-19 | |
| 2012-09-30 | $34.40M 10-Q · filed 2013-10-30 | $69.20M derived: sum of 2 quarters · filed 2013-10-30 | $100.30M 10-Q · filed 2013-10-30 | $136.80M derived: sum of 4 quarters · filed 2014-02-19 | |
| 2012-06-30 | $34.80M 10-Q · filed 2013-07-26 | $65.80M 10-Q · filed 2013-07-26 | $102.40M derived: sum of 3 quarters · filed 2014-02-19 | $138.90M derived: sum of 4 quarters · filed 2014-02-19 | |
| 2012-03-31 | $30.90M 10-Q · filed 2013-04-26 | $67.60M derived: sum of 2 quarters · filed 2014-02-19 | $104.10M derived: sum of 3 quarters · filed 2014-02-19 | $140.40M derived: sum of 4 quarters · filed 2014-02-19 | |
| 2011-12-31 | $36.70M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-19 | $73.20M derived: sum of 2 quarters · filed 2014-02-19 | $109.50M derived: sum of 3 quarters · filed 2014-02-19 | $147.40M 10-K · filed 2014-02-19 | |
| 2011-09-30 | $36.50M 10-Q · filed 2012-10-26 | $72.80M derived: sum of 2 quarters · filed 2012-10-26 | $110.70M 10-Q · filed 2012-10-26 | $166.50M derived: sum of 4 quarters · filed 2013-02-21 | |
| 2011-06-30 | $36.30M 10-Q · filed 2012-07-27 | $74.20M 10-Q · filed 2012-07-27 | $130.00M derived: sum of 3 quarters · filed 2013-02-21 | $176.80M derived: sum of 4 quarters · filed 2013-02-21 | |
| 2011-03-31 | $37.90M 10-Q · filed 2012-04-30 | $93.70M derived: sum of 2 quarters · filed 2013-02-21 | $140.50M derived: sum of 3 quarters · filed 2013-02-21 | $194.90M derived: sum of 4 quarters · filed 2013-02-21 | |
| 2010-12-31 | $55.80M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-21 | $102.60M derived: sum of 2 quarters · filed 2013-02-21 | $157.00M derived: sum of 3 quarters · filed 2013-02-21 | $231.00M 10-K · filed 2013-02-21 | |
| 2010-09-30 | $46.80M 10-Q · filed 2011-10-28 | $101.20M derived: sum of 2 quarters · filed 2011-10-28 | $175.20M 10-Q · filed 2011-10-28 | $279.00M derived: sum of 4 quarters · filed 2012-02-24 | |
| 2010-06-30 | $54.40M 10-Q · filed 2011-07-29 | $128.20M 10-Q · filed 2011-07-29 | $232.20M derived: sum of 3 quarters · filed 2012-02-24 | $336.20M derived: sum of 4 quarters · filed 2012-02-24 | |
| 2010-03-31 | $73.70M 10-Q · filed 2011-04-29 | $177.80M derived: sum of 2 quarters · filed 2012-02-24 | $281.80M derived: sum of 3 quarters · filed 2012-02-24 | $376.10M derived: sum of 4 quarters · filed 2012-02-24 | |
| 2009-12-31 | $104.10M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-24 | $208.10M derived: sum of 2 quarters · filed 2012-02-24 | $302.40M derived: sum of 3 quarters · filed 2012-02-24 | $368.50M 10-K · filed 2012-02-24 | |
| 2009-09-30 | $104.00M 10-Q · filed 2010-10-29 | $198.30M derived: sum of 2 quarters · filed 2010-10-29 | $264.40M 10-Q · filed 2010-10-29 | ||
| 2009-06-30 | $94.30M 10-Q/A · filed 2010-08-02 | $160.40M 10-Q/A · filed 2010-08-02 | |||
| 2008-12-31 | $255.30M 10-K · filed 2011-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Akari Therapeutics Plc (AKTX) | $1,527.991B | -47,921.42 | |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |